Wall Street Zen Upgrades DBV Technologies (NASDAQ:DBVT) to Hold

Wall Street Zen upgraded shares of DBV Technologies (NASDAQ:DBVT - Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Several other brokerages also recently weighed in on DBVT. Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. HC Wainwright lifted their price objective on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 5th. JMP Securities reiterated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price target for the company in a report on Thursday, May 29th. Finally, Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.75.

DBV Technologies Stock Down 3.7%

DBVT stock traded down $0.41 during trading on Friday, hitting $10.60. The company had a trading volume of 18,640 shares, compared to its average volume of 191,235. The firm has a 50-day moving average price of $9.48 and a 200-day moving average price of $6.66. The firm has a market cap of $290.33 million, a PE ratio of -2.15 and a beta of -0.59. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%. The company had revenue of $0.51 million during the quarter. Sell-side analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.